Form 4: Hims & Hers Health, Inc. Executive Soleil Boughton Reports Stock Sales

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., reported selling shares of Class A Common Stock on March 3, 2025, and April 14, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Soleil Boughton, the Chief Legal Officer of Hims & Hers Health, Inc., filed a Form 4 disclosing changes in beneficial ownership.
• The report details the sale of Class A Common Stock on two dates: March 3, 2025, and April 14, 2025.
• On March 3, 2025, 4,151 shares were sold at a price of $45.14 per share.
• On April 14, 2025, 3,236 shares were sold at a price of $28.72 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted on August 28, 2024.
• Following these transactions, Boughton directly owns 162,898 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports stock sales by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of company stock) buy or sell the company's securities. These filings provide transparency into insider transactions and are closely watched by investors for signals about a company's prospects.

Comparison to Industry Standards

• Insider selling is a common occurrence in publicly traded companies.
• The use of Rule 10b5-1 trading plans is a standard practice to allow insiders to sell shares over time while avoiding accusations of trading on non-public information.
• Comparing the trading activity of Hims & Hers Health, Inc. insiders to those of similar companies like Teladoc Health or GoodRx could provide a broader context for understanding the significance of these transactions.

Stakeholder Impact

• Shareholders may interpret insider sales in various ways, sometimes as a lack of confidence in the company's future prospects, although sales under 10b5-1 plans are often pre-scheduled and not necessarily indicative of current sentiment.
• The impact on employees, customers, suppliers, and creditors is likely minimal, as this is a routine disclosure of insider trading activity.

Key Dates

Keywords

Form 4, Hims & Hers Health, Inc., Soleil Boughton, insider trading, stock sale, Rule 10b5-1, Class A Common Stock, beneficial ownership